Review ArticleReview

Personalized immunotherapy in cancer precision medicine

Kazuma Kiyotani, Yujiro Toyoshima and Yusuke Nakamura
Cancer Biology & Medicine November 2021, 18 (4) 955-965; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0032

References

  1. 1.↵
    2. Schwaederle M,
    3. Zhao M,
    4. Lee JJ,
    5. Lazar V,
    6. Leyland-Jones B,
    7. Schilsky RL, et al.
    Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016; 2: 1452–9.
    OpenUrl
  2. 2.↵
    2. Zehir A,
    3. Benayed R,
    4. Shah RH,
    5. Syed A,
    6. Middha S,
    7. Kim HR, et al.
    Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23: 703–13.
    OpenUrlCrossRefPubMed
  3. 3.
    2. Tsimberidou AM,
    3. Iskander NG,
    4. Hong DS,
    5. Wheler JJ,
    6. Falchook GS,
    7. Fu S, et al.
    Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012; 18: 6373–83.
    OpenUrlAbstract/FREE Full Text
  4. 4.
    2. Stockley TL,
    3. Oza AM,
    4. Berman HK,
    5. Leighl NB,
    6. Knox JJ,
    7. Shepherd FA, et al.
    Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 2016; 8: 109.
    OpenUrl
  5. 5.
    2. Meric-Bernstam F,
    3. Brusco L,
    4. Shaw K,
    5. Horombe C,
    6. Kopetz S,
    7. Davies MA, et al.
    Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015; 33: 2753–62.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Sholl LM,
    3. Do K,
    4. Shivdasani P,
    5. Cerami E,
    6. Dubuc AM,
    7. Kuo FC, et al.
    Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016; 1: e87062.
  7. 7.↵
    2. Priestley P,
    3. Baber J,
    4. Lolkema MP,
    5. Steeghs N,
    6. de Bruijn E,
    7. Shale C, et al.
    Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575: 210–6.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Zhao EY,
    3. Torchia J,
    4. Fortuna A,
    5. Torti D,
    6. Yu C,
    7. Shah E, et al.
    Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing. J Clin Oncol. 2020; 38: 3562.
    OpenUrl
  9. 9.↵
    2. Postow MA,
    3. Callahan MK,
    4. Wolchok JD.
    Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33: 1974–82.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Topalian SL,
    3. Hodi FS,
    4. Brahmer JR,
    5. Gettinger SN,
    6. Smith DC,
    7. McDermott DF, et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443–54.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    2. Brahmer JR,
    3. Tykodi SS,
    4. Chow LQ,
    5. Hwu WJ,
    6. Topalian SL,
    7. Hwu P, et al.
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455–65.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Lee HH,
    3. Wang YN,
    4. Xia W,
    5. Chen CH,
    6. Rau KM,
    7. Ye L, et al.
    Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 2019; 36: 168–78 e4.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Goodman AM,
    3. Piccioni D,
    4. Kato S,
    5. Boichard A,
    6. Wang HY,
    7. Frampton G, et al.
    Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 2018; 4: 1237–44.
    OpenUrl
  14. 14.↵
    2. Goodman AM,
    3. Kato S,
    4. Bazhenova L,
    5. Patel SP,
    6. Frampton GM,
    7. Miller V, et al.
    Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017; 16: 2598–608.
    OpenUrlAbstract/FREE Full Text
  15. 15.
    2. Rizvi NA,
    3. Hellmann MD,
    4. Snyder A,
    5. Kvistborg P,
    6. Makarov V,
    7. Havel JJ, et al.
    Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124–8.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Samstein RM,
    3. Lee CH,
    4. Shoushtari AN,
    5. Hellmann MD,
    6. Shen R,
    7. Janjigian YY, et al.
    Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51: 202–6.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Stenzinger A,
    3. Allen JD,
    4. Maas J,
    5. Stewart MD,
    6. Merino DM,
    7. Wempe MM, et al.
    Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019; 58: 578–88.
    OpenUrlPubMed
  18. 18.↵
    2. Marcus L,
    3. Lemery SJ,
    4. Keegan P,
    5. Pazdur R.
    FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019; 25: 3753–8.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    2. Kim ST,
    3. Cristescu R,
    4. Bass AJ,
    5. Kim KM,
    6. Odegaard JI,
    7. Kim K, et al.
    Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24: 1449–58.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Overman MJ,
    3. McDermott R,
    4. Leach JL,
    5. Lonardi S,
    6. Lenz HJ,
    7. Morse MA, et al.
    Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18: 1182–91.
    OpenUrlCrossRefPubMed
  21. 21.
    2. Overman MJ,
    3. Lonardi S,
    4. Wong KYM,
    5. Lenz HJ,
    6. Gelsomino F,
    7. Aglietta M, et al.
    Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018; 36: 773–9.
    OpenUrlCrossRefPubMed
  22. 22.
    2. Le DT,
    3. Kim TW,
    4. Van Cutsem E,
    5. Geva R,
    6. Jager D,
    7. Hara H, et al.
    Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020; 38: 11–9.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Marabelle A,
    3. Le DT,
    4. Ascierto PA,
    5. Di Giacomo AM,
    6. De Jesus-Acosta A,
    7. Delord JP, et al.
    Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient xancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020; 38: 1–10.
    OpenUrlCrossRefPubMed
  24. 24.
    2. Gong J,
    3. Wang C,
    4. Lee PP,
    5. Chu P,
    6. Fakih M.
    Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Canc Netw. 2017; 15: 142–7.
    OpenUrlAbstract/FREE Full Text
  25. 25.
    2. van Gool IC,
    3. Eggink FA,
    4. Freeman-Mills L,
    5. Stelloo E,
    6. Marchi E,
    7. de Bruyn M, et al.
    POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 2015; 21: 3347–55.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Zaretsky JM,
    3. Garcia-Diaz A,
    4. Shin DS,
    5. Escuin-Ordinas H,
    6. Hugo W,
    7. Hu-Lieskovan S, et al.
    Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016; 375: 819–29.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Peng W,
    3. Chen JQ,
    4. Liu C,
    5. Malu S,
    6. Creasy C,
    7. Tetzlaff MT, et al.
    Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202–16.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Lee CK,
    3. Man J,
    4. Lord S,
    5. Links M,
    6. Gebski V,
    7. Mok T, et al.
    Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017; 12: 403–7.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Miyauchi E,
    3. Matsuda T,
    4. Kiyotani K,
    5. Low SK,
    6. Hsu YW,
    7. Tsukita Y, et al.
    Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations. Cancer Sci. 2019; 110: 867–74.
    OpenUrl
  30. 30.↵
    2. Koyama S,
    3. Akbay EA,
    4. Li YY,
    5. Aref AR,
    6. Skoulidis F,
    7. Herter-Sprie GS, et al.
    STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016; 76: 999–1008.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Cristescu R,
    3. Mogg R,
    4. Ayers M,
    5. Albright A,
    6. Murphy E,
    7. Yearley J, et al.
    Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018; 362: eaar3593.
  32. 32.↵
    2. Inoue H,
    3. Park JH,
    4. Kiyotani K,
    5. Zewde M,
    6. Miyashita A,
    7. Jinnin M, et al.
    Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology. 2016; 5: e1204507.
  33. 33.↵
    2. Olugbile S,
    3. Kiyotani K,
    4. Park J,
    5. Hoffman P,
    6. Szeto L,
    7. Patel J, et al.
    Early and sustained oligoclonal T cell expansion correlates with durable response to immune checkpoint blockade in lung cancer. J Cancer Sci Ther. 2017; 9: 717–22.
    OpenUrl
  34. 34.
    2. Haymaker CL,
    3. Kim D,
    4. Uemura M,
    5. Vence LM,
    6. Phillip A,
    7. McQuail N, et al.
    Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res. 2017; 5: 100–5.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    2. Kato T,
    3. Kiyotani K,
    4. Tomiyama E,
    5. Koh Y,
    6. Matsushita M,
    7. Hayashi Y, et al.
    Early T cell changes predict clinical response for anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. Oncoimmunology. 2020; 10: e1862948.
  36. 36.↵
    2. Schumacher TN,
    3. Schreiber RD.
    Neoantigens in cancer immunotherapy. Science. 2015; 348: 69–74.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    2. De Plaen E,
    3. Lurquin C,
    4. Van Pel A,
    5. Mariame B,
    6. Szikora JP,
    7. Wolfel T, et al.
    Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc Natl Acad Sci USA. 1988; 85: 2274–8.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Monach PA,
    3. Meredith SC,
    4. Siegel CT,
    5. Schreiber H.
    A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995; 2: 45–59.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    2. Rooney MS,
    3. Shukla SA,
    4. Wu CJ,
    5. Getz G,
    6. Hacohen N.
    Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160: 48–61.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    2. Brown SD,
    3. Warren RL,
    4. Gibb EA,
    5. Martin SD,
    6. Spinelli JJ,
    7. Nelson BH, et al.
    Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014; 24: 743–50.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    2. Giannakis M,
    3. Mu XJ,
    4. Shukla SA,
    5. Qian ZR,
    6. Cohen O,
    7. Nishihara R, et al.
    Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016; 17: 1206.
    OpenUrlCrossRefPubMed
  42. 42.↵
    2. Howitt BE,
    3. Shukla SA,
    4. Sholl LM,
    5. Ritterhouse LL,
    6. Watkins JC,
    7. Rodig S, et al.
    Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015; 1: 1319–23.
    OpenUrlPubMed
  43. 43.↵
    2. Yap KL,
    3. Kiyotani K,
    4. Tamura K,
    5. Antic T,
    6. Jang M,
    7. Montoya M, et al.
    Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res. 2014; 20: 6605–17.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    2. Choudhury NJ,
    3. Kiyotani K,
    4. Yap KL,
    5. Campanile A,
    6. Antic T,
    7. Yew PY, et al.
    Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus. 2016; 2: 445–52.
    OpenUrl
  45. 45.↵
    2. Kiyotani K,
    3. Park JH,
    4. Inoue H,
    5. Husain A,
    6. Olugbile S,
    7. Zewde M, et al.
    Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology. 2017; 6: e1278330.
  46. 46.↵
    2. Kato T,
    3. Park JH,
    4. Kiyotani K,
    5. Ikeda Y,
    6. Miyoshi Y,
    7. Nakamura Y.
    Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget. 2017; 8: 62029–38.
    OpenUrl
  47. 47.↵
    2. Akiyoshi T,
    3. Tanaka N,
    4. Kiyotani K,
    5. Gotoh O,
    6. Yamamoto N,
    7. Oba K, et al.
    Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019; 106: 1381–92.
    OpenUrl
  48. 48.↵
    2. Akiyoshi T,
    3. Gotoh O,
    4. Tanaka N,
    5. Kiyotani K,
    6. Yamamoto N,
    7. Ueno M, et al.
    T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol Immunother. 2020; 70: 509–18.
    OpenUrl
  49. 49.↵
    2. Kiyotani K,
    3. Chan HT,
    4. Nakamura Y.
    Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018; 109: 542–9.
    OpenUrlCrossRefPubMed
  50. 50.↵
    2. Szolek A,
    3. Schubert B,
    4. Mohr C,
    5. Sturm M,
    6. Feldhahn M,
    7. Kohlbacher O.
    OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014; 30: 3310–6.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    2. Shukla SA,
    3. Rooney MS,
    4. Rajasagi M,
    5. Tiao G,
    6. Dixon PM,
    7. Lawrence MS, et al.
    Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015; 33: 1152–8.
    OpenUrlCrossRefPubMed
  52. 52.↵
    2. Kiyotani K,
    3. Mai TH,
    4. Nakamura Y.
    Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. J Hum Genet. 2017; 62: 397–405.
    OpenUrlPubMed
  53. 53.↵
    2. Wang K,
    3. Li M,
    4. Hakonarson H.
    ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38: e164.
  54. 54.↵
    2. Karasaki T,
    3. Nagayama K,
    4. Kuwano H,
    5. Nitadori JI,
    6. Sato M,
    7. Anraku M, et al.
    Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. Cancer Sci. 2017; 108: 170–7.
    OpenUrlCrossRefPubMed
  55. 55.↵
    2. Sykulev Y,
    3. Joo M,
    4. Vturina I,
    5. Tsomides TJ,
    6. Eisen HN.
    Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996; 4: 565–71.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    2. Vita R,
    3. Overton JA,
    4. Greenbaum JA,
    5. Ponomarenko J,
    6. Clark JD,
    7. Cantrell JR, et al.
    The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015; 43: D405–12.
    OpenUrlCrossRefPubMed
  57. 57.
    2. Nielsen M,
    3. Lundegaard C,
    4. Worning P,
    5. Lauemoller SL,
    6. Lamberth K,
    7. Buus S, et al.
    Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003; 12: 1007–17.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.
    2. Lundegaard C,
    3. Lamberth K,
    4. Harndahl M,
    5. Buus S,
    6. Lund O,
    7. Nielsen M.
    NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008; 36: W509–12.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    2. Nielsen M,
    3. Lundegaard C,
    4. Blicher T,
    5. Lamberth K,
    6. Harndahl M,
    7. Justesen S, et al.
    NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007; 2: e796.
  60. 60.↵
    2. Harndahl M,
    3. Rasmussen M,
    4. Roder G,
    5. Dalgaard Pedersen I,
    6. Sorensen M,
    7. Nielsen M, et al.
    Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol. 2012; 42: 1405–16.
    OpenUrlCrossRefPubMed
  61. 61.
    2. Nielsen M,
    3. Lundegaard C,
    4. Lund O,
    5. Kesmir C.
    The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005; 57: 33–41.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    2. Larsen MV,
    3. Lundegaard C,
    4. Lamberth K,
    5. Buus S,
    6. Brunak S,
    7. Lund O, et al.
    An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol. 2005; 35: 2295–303.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    2. Phloyphisut P,
    3. Pornputtapong N,
    4. Sriswasdi S,
    5. Chuangsuwanich E.
    MHCSeqNet: a deep neural network model for universal MHC binding prediction. BMC Bioinformatics. 2019; 20: 270.
    OpenUrlCrossRef
  64. 64.
    2. Wu J,
    3. Wang W,
    4. Zhang J,
    5. Zhou B,
    6. Zhao W,
    7. Su Z, et al.
    DeepHLApan: a deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity. Front Immunol. 2019; 10: 2559.
    OpenUrlCrossRef
  65. 65.↵
    2. Liu G,
    3. Li D,
    4. Li Z,
    5. Qiu S,
    6. Li W,
    7. Chao CC, et al.
    PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity. Gigascience. 2017; 6: 1–11.
    OpenUrlCrossRefPubMed
  66. 66.↵
    2. Gopanenko AV,
    3. Kosobokova EN,
    4. Kosorukov VS.
    Main strategies for the identification of neoantigens. Cancers (Basel). 2020; 12: 2879.
    OpenUrl
  67. 67.↵
    2. Kato T,
    3. Matsuda T,
    4. Ikeda Y,
    5. Park JH,
    6. Leisegang M,
    7. Yoshimura S, et al.
    Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget. 2018; 9: 11009–19.
    OpenUrl
  68. 68.↵
    2. Matsuda T,
    3. Leisegang M,
    4. Park JH,
    5. Ren L,
    6. Kato T,
    7. Ikeda Y, et al.
    Induction of neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer. Clin Cancer Res. 2018; 24: 5357–67.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    2. Ren L,
    3. Leisegang M,
    4. Deng B,
    5. Matsuda T,
    6. Kiyotani K,
    7. Kato T, et al.
    Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. Oncoimmunology. 2019; 8: e1568813.
  70. 70.↵
    2. Lu YC,
    3. Yao X,
    4. Crystal JS,
    5. Li YF,
    6. El-Gamil M,
    7. Gross C, et al.
    Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20: 3401–10.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    2. McGranahan N,
    3. Rosenthal R,
    4. Hiley CT,
    5. Rowan AJ,
    6. Watkins TBK,
    7. Wilson GA, et al.
    Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017; 171: 1259–71 e11.
    OpenUrlCrossRefPubMed
  72. 72.↵
    2. Rosenberg SA,
    3. Yang JC,
    4. Sherry RM,
    5. Kammula US,
    6. Hughes MS,
    7. Phan GQ, et al.
    Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550–57.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    2. Forget MA,
    3. Haymaker C,
    4. Hess KR,
    5. Meng YJ,
    6. Creasy C,
    7. Karpinets T, et al.
    Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res. 2018; 24: 4416–28.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    2. Yoshitake Y,
    3. Fukuma D,
    4. Yuno A,
    5. Hirayama M,
    6. Nakayama H,
    7. Tanaka T, et al.
    Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015; 21: 312–21.
    OpenUrlAbstract/FREE Full Text
  75. 75.
    2. Hazama S,
    3. Nakamura Y,
    4. Tanaka H,
    5. Hirakawa K,
    6. Tahara K,
    7. Shimizu R, et al.
    A phase IotaI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med. 2014; 12: 108.
    OpenUrl
  76. 76.↵
    2. Yasuda T,
    3. Nishiki K,
    4. Hiraki Y,
    5. Kato H,
    6. Iwama M,
    7. Shiraishi O, et al.
    Phase II adjuvant cancer-specific vaccine therapy for esophageal cancer patients curatively resected after preoperative therapy with pathologically positive nodes; possible significance of tumor immune microenvironment in its clinical effects. Ann Surg. 2020; in press.
  77. 77.↵
    2. Sahin U,
    3. Derhovanessian E,
    4. Miller M,
    5. Kloke BP,
    6. Simon P,
    7. Lower M, et al.
    Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547: 222–6.
    OpenUrlCrossRefPubMed
  78. 78.↵
    2. Ott PA,
    3. Hu Z,
    4. Keskin DB,
    5. Shukla SA,
    6. Sun J,
    7. Bozym DJ, et al.
    An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547: 217–21.
    OpenUrlCrossRefPubMed
  79. 79.↵
    2. Keskin DB,
    3. Anandappa AJ,
    4. Sun J,
    5. Tirosh I,
    6. Mathewson ND,
    7. Li S, et al.
    Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019; 565: 234–9.
    OpenUrlPubMed
  80. 80.↵
    2. Hilf N,
    3. Kuttruff-Coqui S,
    4. Frenzel K,
    5. Bukur V,
    6. Stevanovic S,
    7. Gouttefangeas C, et al.
    Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019; 565: 240–5.
    OpenUrlCrossRefPubMed
  81. 81.↵
    2. Ott PA,
    3. Hu-Lieskovan S,
    4. Chmielowski B,
    5. Govindan R,
    6. Naing A,
    7. Bhardwaj N, et al.
    A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020; 183: 347–62 e24.
    OpenUrlCrossRefPubMed
  82. 82.↵
    2. Rosenberg SA,
    3. Restifo NP.
    Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348: 62–8.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    2. Morgan RA,
    3. Dudley ME,
    4. Wunderlich JR,
    5. Hughes MS,
    6. Yang JC,
    7. Sherry RM, et al.
    Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314: 126–9.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    2. Robbins PF,
    3. Morgan RA,
    4. Feldman SA,
    5. Yang JC,
    6. Sherry RM,
    7. Dudley ME, et al.
    Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29: 917–24.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    2. Rapoport AP,
    3. Stadtmauer EA,
    4. Binder-Scholl GK,
    5. Goloubeva O,
    6. Vogl DT,
    7. Lacey SF, et al.
    NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015; 21: 914–21.
    OpenUrlCrossRefPubMed
  86. 86.↵
    2. Leisegang M,
    3. Engels B,
    4. Schreiber K,
    5. Yew PY,
    6. Kiyotani K,
    7. Idel C, et al.
    Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation. Clin Cancer Res. 2016; 22: 2734–43.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    2. Leisegang M,
    3. Kammertoens T,
    4. Uckert W,
    5. Blankenstein T.
    Targeting human melanoma neoantigens by T cell receptor gene therapy. J Clin Invest. 2016; 126: 854–8.
    OpenUrlCrossRefPubMed
  88. 88.
    2. Massard C,
    3. Michiels S,
    4. Ferte C,
    5. Le Deley MC,
    6. Lacroix L,
    7. Hollebecque A, et al.
    High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017; 7: 586–95.
    OpenUrlAbstract/FREE Full Text
  89. 89.
    2. Cobain EF,
    3. Robinson DR,
    4. Wu Y-M,
    5. Everett J,
    6. Rabban E,
    7. Kumar C, et al.
    Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults. J Clin Oncol. 2017; 35: 35.
    OpenUrl
  90. 90.
    2. Tredan O,
    3. Wang Q,
    4. Pissaloux D,
    5. Cassier P,
    6. de la Fouchardiere A,
    7. Fayette J, et al.
    Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol. 2019; 30: 757–65.
    OpenUrlCrossRefPubMed
  91. 91.
    2. Carreno BM,
    3. Magrini V,
    4. Becker-Hapak M,
    5. Kaabinejadian S,
    6. Hundal J,
    7. Petti AA, et al.
    A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348: 803–8.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords